Review: assessment of the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin, docetaxel and bevacizumab when used to treat GI malignancy. It will also examine how these drugs are used (appropriate use, ‘doeltrefffende toepassing’)in GI treatment.